MANDEEP BAJAJ to Drug Therapy, Combination
This is a "connection" page, showing publications MANDEEP BAJAJ has written about Drug Therapy, Combination.
Connection Strength
0.478
-
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med. 2014 Dec; 31(12):1505-14.
Score: 0.090
-
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia. 2011 Dec; 54(12):3093-100.
Score: 0.074
-
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring). 2011 Dec; 19(12):2310-5.
Score: 0.072
-
Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous souffl?. Metab Syndr Relat Disord. 2009 Apr; 7(2):79-81.
Score: 0.062
-
Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia. 2007 Aug; 50(8):1723-31.
Score: 0.055
-
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.
Score: 0.029
-
Extraocular muscle cysticercosis: never skip steroids. BMJ Case Rep. 2018 Jan 09; 2018.
Score: 0.029
-
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
Score: 0.027
-
Role of oral corticosteroids in orbital cellulitis. Am J Ophthalmol. 2013 Jul; 156(1):178-183.e1.
Score: 0.021
-
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012 Dec; 26(6):445-56.
Score: 0.020